Nubeqa
Chemical Name | darolutamide |
Dosage Form | Tablet (oral; 300 mg) |
Drug Class | Receptor antagonists |
System | Male reproductive |
Company | Bayer HealthCare Pharmaceuticals Inc. |
Approval Year | 2019 |
Indication
- Nubeqa is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.